Atrogi announces first patient treated with its ATR-258 ß2 adrenoceptor agonist

Key2Compliance are happy to celebrate that our client, Atrogi, has announced first patient treated with its ATR-258 ß₂-adrenoceptor agonist in their ongoing phase 1 study for the treatment of Type 2 Diabetes.

Atrogi is an early-stage Swedish pharma company developing a novel solution for the treatment of Type 2 Diabetes. The trial is expected to be completed in mid-2023.

Key2Compliance supports the Atrogi team with clinical project management of the study, that is conducted in Germany, and we are thrilled to be part of this very interesting study.

Read the press release from Atrogi here.

About Atrogi
Atrogi, a Swedish pharmaceutical R&D company, develops a revolutionizing solution for the treatment of type 2 diabetes aimed at the global market. Atrogi was founded in 2013 based on results from professor Tore Bengtsson. Please visit: www.atrogi.com